GT Biopharma Inc (GTBPXXXX)
Institutional ownership reported to the SEC as of Q4 2024, across 17 quarters.
1
Reporting holders
$4.5K
Reported value
0.0%
Held as options
+0
Holder change
Options share is the part of reported value carried in derivative lines rather than shares. A high figure means institutions are expressing a view on this security without owning much of it.
Holders
| Filer | Value | Shares | Their book | Held | Change |
|---|---|---|---|---|---|
| VSM Wealth Advisory, LLC | $4.5K | 501 | 0.00% | new | FIRST |
Quarter by quarter
Coverage begins with the quarter ending 2018-12-31. Earlier filings exist only as occasional late amendments, too sparse to describe a market, so they are not shown.
| Quarter | Holders | Value | Shares | New | Added | Trimmed | Options |
|---|---|---|---|---|---|---|---|
| Q4 2024 | 1 | $4.5K | 501 | 0 | 0 | 0 | 0.0% |
| Q1 2024 | 1 | $4 | 1 | 0 | 0 | 1 | 0.0% |
| Q4 2023 | 27 | $855.1K | 3,283,125 | 5 | 6 | 4 | 0.0% |
| Q3 2023 | 27 | $795.9K | 3,204,913 | 3 | 7 | 6 | 0.0% |
| Q2 2023 | 30 | $1.0M | 3,068,573 | 5 | 4 | 8 | 0.0% |
| Q1 2023 | 28 | $2.9M | 5,073,937 | 4 | 6 | 6 | 0.1% |
| Q4 2022 | 25 | $5.1M | 5,774,773 | 6 | 6 | 3 | 0.0% |
| Q3 2022 | 31 | $4.4M | 2,478,564 | 2 | 4 | 13 | 0.0% |
| Q2 2022 | 43 | $9.3M | 3,106,579 | 4 | 11 | 17 | 0.7% |
| Q1 2022 | 54 | $13.1M | 4,472,135 | 8 | 5 | 27 | 1.6% |
| Q4 2021 | 52 | $17.4M | 5,534,435 | 8 | 23 | 6 | 3.2% |
| Q3 2021 | 53 | $33.6M | 4,757,638 | 15 | 13 | 17 | 4.4% |
| Q2 2021 | 48 | $69.9M | 4,511,271 | 34 | 8 | 4 | 0.0% |
| Q1 2021 | 18 | $4.0M | 581,478 | 18 | 0 | 0 | 0.0% |
| Q2 2019 | 1 | $10.0K | 42,949 | 0 | 0 | 0 | 0.0% |
| Q1 2019 | 1 | $15.0K | 42,949 | 0 | 0 | 0 | 0.0% |
| Q4 2018 | 1 | $28.0K | 42,949 | 0 | 0 | 0 | 0.0% |